New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTBKS, CVRR, PXD, SQBG, OMI, MDCI, GLNG, AERI, NSPH, BMY, GIS, MON, IMSOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
Check below for free stories on BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 8, 2014
17:17 EDTGISAnnie's up over 37% after General Mills to buy company for $46 per share
Subscribe for More Information
17:05 EDTGISGeneral Mills to buy Annie's for $46 per share in cash
Subscribe for More Information
17:02 EDTGISGeneral Mills to buy Annie's for $46 per share in cash
Subscribe for More Information
15:27 EDTBKSNotable companies reporting before tomorrow's open
Subscribe for More Information
13:53 EDTBKSBarnes & Noble September volatility increases into Q1 and guidance
Subscribe for More Information
07:43 EDTGLNGGolar LNG price target raised to $75 from $68 at BofA/Merrill
BofA/Merrill raised Golar's price target to $75 given the commitment to a second floating LNG liquidfication, or FLNG, unit conversion, and firming contracts on the first FNLG. Shares are Buy rated.
September 5, 2014
16:58 EDTSQBGSequential files to sell 14.33M shares of common stocks, warrants for 3M shares
16:45 EDTBMYMarket ends week little changed after mixed economic data
Subscribe for More Information
14:42 EDTMONCHS Inc. names David Black as Chief Information Officer
Subscribe for More Information
11:17 EDTBMYBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
09:18 EDTGLNGGolar LNG 27.8M share Secondary priced at $58.50
Subscribe for More Information
09:16 EDTGLNGOn The Fly: Pre-market Movers
Subscribe for More Information
08:18 EDTBKSBarnes & Noble September volatility elevated into Q1 and guidance
Barnes & Noble September call option implied volatility is at 63, October is at 49, January is at 45; compared to its 26-week average of 46 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on September 9.
06:28 EDTAERIAerie Pharmaceuticals to host investor day
Subscribe for More Information
September 4, 2014
16:46 EDTGLNGGolar LNG offers 27.83M shares of common stock by World Shipholding
BofA Merrill Lynch, Citigroup, Goldman, Sachs & Co., Morgan Stanley and RS Platou Markets AS are acting as joint book-running managers and Arctic Securities, BNP PARIBAS, DNB Markets and Pareto Securities are acting as co-managers in the offering.
16:03 EDTNSPHNanosphere hires Jefferies to review strategic alternatives
Subscribe for More Information
09:34 EDTGLNGGolar LNG announces partnershp and shareholder agreement with Keppel
Subscribe for More Information
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
September 3, 2014
11:08 EDTMDCIGabelli raises stake in Medical Action to 7.86% from 6.85%
Subscribe for More Information
07:34 EDTAERIAerie Pharmaceuticals initiates Phase 3 registration trial of Rhopressa
Aerie Pharmaceuticals announced that on August 29, dosing commenced of the first patients enrolled in the company’s Phase 3 registration trial in Canada of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. The study, named “Rocket 3,” is designed to evaluate safety and tolerability of Rhopressa in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The company recently announced the commencement of two Phase 3 trials in the United States, “Rocket 1” and “Rocket 2,” which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa. Pending progress of the Rhopressa Phase 3 program and regulatory approvals, Aerie intends to commercialize Rhopressa in North American markets with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use